A Phase 1/2 interventional study of Galunisertib and Nivolumab in Solid Tumor, Non-Small Cell Lung Cancer Recurrent and Hepatocellular Carcinoma Recurrent, sponsored by Eli Lilly and Company. Completed at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-09.
Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company — none open to participants now, none under way, none of them phase 3. Carcinoma, Hepatocellular · Eli Lilly and Company.
Among the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company, this one is the 9th largest by enrollment, is one of 2 that started in 2015, is one of 3 in phase 1/2, and was the 9th registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.
Browse Carcinoma, Hepatocellular studies →None of the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company is open now. The open studies under Carcinoma, Hepatocellular, anywhere →
Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 2
First in 2008; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 54 across 2,619 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 47 across the 13 interventional studies. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety, tolerability, and efficacy of the study drug known as galunisertib in combination with nivolumab in participants with advanced refractory solid tumors and in recurrent or refractory non-small cell lung cancer (NSCLC) or hepatocellular carcinoma (HCC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For NSCLC:
Participants who completed and progressed on a platinum-containing regimen as adjuvant, neoadjuvant, or part of a course of chemoradiation therapy given from locally advanced disease and developed recurrent (local or ) disease within the 6 months before screening would be counted as having received 1 prior platinum-containing regimen and therefore would not require re-treatment with a platinum-containing regimen for Stage IIIB, IV, or recurrent disease and are eligible. However, participants must have received at least 2 cycles of a platinum doublet based chemotherapy before discontinuation for toxicity. If participants received only one cycle of a platinum doublet and discontinue due to clear progression, that regimen should be counted as a prior line of therapy.
For HCC:
Exclusion Criteria:
Have moderate or severe cardiovascular disease:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50 milligrams (mg) Galunisertib administered orally once daily (QD) on Day 1 through Day 14 of each 4-week cycle in combination with 3 milligrams per kilogram (3 mg/kg) nivolumab given intravenously (IV), every 2 weeks (Q2W), (Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
Drug: Galunisertib · Drug: Nivolumab
50 mg Galunisertib administered orally twice daily (BID) on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W,(Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
Drug: Galunisertib · Drug: Nivolumab
80 mg Galunisertib administered orally BID on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
Drug: Galunisertib · Drug: Nivolumab
150 mg Galunisertib administered orally BID on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W,(Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
Drug: Galunisertib · Drug: Nivolumab
150 mg Galunisertib administered orally BID for the first 14 days of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15) of each 4-week cycle. Participants may continue to receive study drug until discontinuation criteria are met.
Drug: Galunisertib · Drug: Nivolumab
150 mg Galunisertib administered orally BID for the first 14 days of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15) of each 4-week cycle. Participants may continue to receive study drug until discontinuation criteria are met.
Drug: Galunisertib · Drug: Nivolumab
Administered orally
Also known as: LY2157299
Administered IV
Also known as: OPDIVO®
Phase 1b: Maximum Tolerated Dose (MTD) of Galunisertib in Combination With Nivolumab
The MTD is defined as the highest tested dose that has less than 33% probability of causing a dose limiting toxicity (DLT).
Time frame: Cycle 1 through Cycle 2 (Up to 2 Months)
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Nivolumab
Minimum Concentration (Cmin) of Nivolumab
Time frame: PK: Cycle 1 Day 15 Predose; Cycle 2: Day 1: Pre-dose; Day 15: Predose: Cycle 4: Day 1: Predose
PK: Area Under the Plasma Concentration -Time Curve of Galunisertib From Time Zero to 24 Hours (AUC [0-24h]) at Steady State
Area under the plasma concentration curve from time zero to 24 hours of galunisertib for Cycle 1 and Cycle 2.
Time frame: PK: Cycle 1 and Cycle 2 Day 1: Predose, 0.5 - 3 hours postdose, Cycle 1 and Cycle 2 Day 14: Predose, 0.5 - 2, 3.5 - 5, and 24 hours postdose through Cycle 4 Day 1 predose
Number of Participants With Anti-Nivolumab Antibodies When Administered in Combination With Galunisertib
Participants with treatment-emergent anti-nivolumab antibodies when administered with galunisertib were participants with a 4-fold or greater increase in titer from baseline measurement (treatment-boosted). If baseline result is ADA not present, then the subject is TE ADA+, if there is at least 1 postbaseline result of ADA present with titer ≥ 40 (treatment-induced).
Time frame: Cycle 1: Days 1, 14, 15 Predose and Day 100 Follow-up; Cycles 2 and 4: Day 1 Predose and Day 100 Follow-up
Phase 2: Progression Free Survival (PFS)
PFS was defined as the time from the date of first study treatment to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.
Time frame: Date of First Study Treatment to Measured Progressive Disease or Death (Up to 35 Months)
Phase 2: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response: Objective Response Rate (ORR)
Objective Response Rate was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.
Time frame: Baseline to Measured Progressive Disease (Up to 35 Months)
Phase 2: Duration of Response (DoR)
Duration of response was measured from the date of documented response to the date of first progression of disease or the date of death due to any cause, whichever is earlier.
Time frame: Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Up to 35 Months)
Phase 2: Time to Response
Time to response was measured from the date of first study treatment to the first documented response of Complete Response (CR) or Partial Response (PR).
Time frame: Date of First Study Treatment to Date of Complete Response or Partial Response (Up to 35 Months)
Phase 2: Overall Survival (OS)
Overall Survival was determined from the date of first study treatment until death due to any cause.
Time frame: Date of First Study Treatment to Death from Any Cause (Up to 35 Months)
Due low enrollment, the Hepatocellular Carcinoma (HCC) cohort was terminated early.
| Milestone | Galunisertib + Nivolumab (Cohort 1) Phase 1b | Galunisertib + Nivolumab (Cohort 2) Phase 1b | Galunisertib + Nivolumab (Cohort 3) Phase 1b | Galunisertib + Nivolumab (Cohort 4) Phase 1b | Galunisertib + Nivolumab - Non-Small Cell Lung Cancer (NSCLC) Phase 2 | Galunisertib + Nivolumab - Hepatocellular Carcinoma (HCC) Phase 2 |
|---|---|---|---|---|---|---|
| Started | 3 | 5 | 3 | 4 | 25 | 1 |
| Received at least one dose of study drug | 3 | 5 | 3 | 4 | 25 | 1 |
| Completed | 3 | 4 | 3 | 4 | 20 | 1 |
| Not completed | 0 | 1 | 0 | 0 | 5 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 0 |
The MTD is defined as the highest tested dose that has less than 33% probability of causing a dose limiting toxicity (DLT).
| milligrams (mg) | Phase 1b Participants |
|---|---|
| Phase 1b: Maximum Tolerated Dose (MTD) of Galunisertib in Combination With Nivolumab | 300 |
Minimum Concentration (Cmin) of Nivolumab
| micrograms per milliliter (µg/mL) | Galunisertib + Nivolumab (Cohort 1) Phase 1b | Galunisertib + Nivolumab (Cohort 2) Phase 1b | Galunisertib + Nivolumab (Cohort 3) Phase 1b | Galunisertib + Nivolumab (Cohort 4) Phase 1b | Galunisertib + Nivolumab (NSCLC) Phase 2 | Galunisertib + Nivolumab ( HCC) Phase 2 |
|---|---|---|---|---|---|---|
| Pharmacokinetics (PK): Minimum Concentration (Cmin) of Nivolumab | 33.5 (19.9 to 53.6) | 36.2 (11.8 to 58.1) | 43.2 (5.45 to 76) | 29.2 (9.39 to 63.7) | 37.6 (1.08 to 105) | — |
Area under the plasma concentration curve from time zero to 24 hours of galunisertib for Cycle 1 and Cycle 2.
| micrograms*hour per liter (μg*h/L) | Galunisertib + Nivolumab (Cohort 1) Phase 1b | Galunisertib + Nivolumab (Cohort 2) Phase 1b | Galunisertib + Nivolumab (Cohort 3) Phase 1b | Galunisertib + Nivolumab (Cohort 4) Phase 1b | Galunisertib + Nivolumab (NSCLC ) Phase 2 | Galunisertib + Nivolumab ( HCC) Phase 2 |
|---|---|---|---|---|---|---|
| PK: Area Under the Plasma Concentration -Time Curve of Galunisertib From Time Zero to 24 Hours (AUC [0-24h]) at Steady State | 3060 ± 41 | 2350 ± 46 | 2220 ± 164 | 5580 ± 61 | 7322 ± 67 | NA ± NA |
Participants with treatment-emergent anti-nivolumab antibodies when administered with galunisertib were participants with a 4-fold or greater increase in titer from baseline measurement (treatment-boosted). If baseline result is ADA not present, then the subject is TE ADA+, if there is at least 1 postbaseline result of ADA present with titer ≥ 40 (treatment-induced).
| Participants | Galunisertib + Nivolumab (Cohort 1) Phase 1b | Galunisertib + Nivolumab (Cohort 2) Phase 1b | Galunisertib + Nivolumab (Cohort 3) Phase 1b | Galunisertib + Nivolumab (Cohort 4) Phase 1b | Galunisertib + Nivolumab (NSCLC) Phase 2 | Galunisertib + Nivolumab (HCC) Phase 2 |
|---|---|---|---|---|---|---|
| Number of Participants With Anti-Nivolumab Antibodies When Administered in Combination With Galunisertib | 0 | 0 | 0 | 0 | 0 | 0 |
PFS was defined as the time from the date of first study treatment to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.
| months | Galunisertib + Nivolumab (NSCLC) Phase 2 | Galunisertib + Nivolumab (HCC) Phase 2 |
|---|---|---|
| Phase 2: Progression Free Survival (PFS) | 5.26 (1.77 to 9.20) | 5.39 |
Objective Response Rate was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.
| Percentage of Participants | Galunisertib + Nivolumab (NSCLC) Phase 2 | Galunisertib + Nivolumab (HCC) Phase 2 |
|---|---|---|
| Phase 2: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response: Objective Response Rate (ORR) | 24.0 | 0 |
Duration of response was measured from the date of documented response to the date of first progression of disease or the date of death due to any cause, whichever is earlier.
| months | Galunisertib + Nivolumab (NSCLC) Phase 2 | Galunisertib + Nivolumab (HCC) Phase 2 |
|---|---|---|
| Phase 2: Duration of Response (DoR) | 9.03 (1.97 to 35) | — |
Time to response was measured from the date of first study treatment to the first documented response of Complete Response (CR) or Partial Response (PR).
| months | Galunisertib + Nivolumab (NSCLC) Phase 2 | Galunisertib + Nivolumab (HCC) Phase 2 |
|---|---|---|
| Phase 2: Time to Response | 4.2 (0.5 to 35) | — |
Overall Survival was determined from the date of first study treatment until death due to any cause.
| months | Galunisertib + Nivolumab (NSCLC) Phase 2 | Galunisertib + Nivolumab (HCC) Phase 2 |
|---|---|---|
| Phase 2: Overall Survival (OS) | 11.99 (8.15 to 16.23) | 14.52 |
Collected over Up to 35 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Galunisertib + Nivolumab (Cohort 1) Phase 1b | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Galunisertib + Nivolumab (Cohort 2) Phase 1b | 4/5 (80%) | 2/5 (40%) | 4/5 (80%) |
| Galunisertib + Nivolumab (Cohort 3) Phase 1b | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Galunisertib + Nivolumab (Cohort 4) Phase 1b | 3/4 (75%) | 2/4 (50%) | 4/4 (100%) |
| Galunisertib + Nivolumab (NSCLC) Phase 2 | 17/25 (68%) | 13/25 (52%) | 23/25 (92%) |
| Galunisertib + Nivolumab (HCC) Phase 2 | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) |
| Event | Galunisertib + Nivolumab (Cohort 1) Phase 1b | Galunisertib + Nivolumab (Cohort 2) Phase 1b | Galunisertib + Nivolumab (Cohort 3) Phase 1b | Galunisertib + Nivolumab (Cohort 4) Phase 1b | Galunisertib + Nivolumab (NSCLC) Phase 2 | Galunisertib + Nivolumab (HCC) Phase 2 |
|---|---|---|---|---|---|---|
| DyspepsiaGastrointestinal disorders | 0/3 | 0/5 | 1/3 | 0/4 | 0/25 | 0/1 |
| Large intestinal obstructionGastrointestinal disorders | 0/3 | 0/5 | 1/3 | 0/4 | 0/25 | 0/1 |
| VomitingGastrointestinal disorders | 1/3 | 0/5 | 0/3 | 0/4 | 0/25 | 0/1 |
| PyelonephritisInfections and infestations | 0/3 | 0/5 | 1/3 | 0/4 | 0/25 | 0/1 |
| DehydrationMetabolism and nutrition disorders | 0/3 | 0/5 | 1/3 | 0/4 | 0/25 | 0/1 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/3 | 0/5 | 0/3 | 0/4 | 0/25 | 0/1 |
| HydronephrosisRenal and urinary disorders | 0/3 | 0/5 | 1/3 | 0/4 | 0/25 | 0/1 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/3 | 0/5 | 0/3 | 0/4 | 0/25 | 0/1 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/3 | 0/5 | 0/3 | 0/4 | 2/25 | 0/1 |
| Small intestinal obstructionGastrointestinal disorders | 0/3 | 0/5 | 0/3 | 1/4 | 0/25 | 0/1 |
| Event | Galunisertib + Nivolumab (Cohort 1) Phase 1b | Galunisertib + Nivolumab (Cohort 2) Phase 1b | Galunisertib + Nivolumab (Cohort 3) Phase 1b | Galunisertib + Nivolumab (Cohort 4) Phase 1b | Galunisertib + Nivolumab (NSCLC) Phase 2 | Galunisertib + Nivolumab (HCC) Phase 2 |
|---|---|---|---|---|---|---|
| GingivitisInfections and infestations | 0/3 | 0/5 | 0/3 | 0/4 | 0/25 | 1/1 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/3 | 0/5 | 0/3 | 0/4 | 0/25 | 1/1 |
| Amylase increasedInvestigations | 0/3 | 0/5 | 0/3 | 3/4 | 2/25 | 0/1 |
| VomitingGastrointestinal disorders | 2/3 | 0/5 | 1/3 | 0/4 | 3/25 | 0/1 |
| NauseaGastrointestinal disorders | 1/3 | 1/5 | 1/3 | 2/4 | 6/25 | 0/1 |
| Non-cardiac chest painGeneral disorders | 0/3 | 0/5 | 0/3 | 2/4 | 1/25 | 0/1 |
| Aspartate aminotransferase increasedInvestigations | 0/3 | 0/5 | 0/3 | 2/4 | 2/25 | 0/1 |
| Blood alkaline phosphatase increasedInvestigations | 0/3 | 0/5 | 0/3 | 2/4 | 1/25 | 0/1 |
| Gamma-glutamyltransferase increasedInvestigations | 0/3 | 0/5 | 0/3 | 2/4 | 2/25 | 0/1 |
| Lipase increasedInvestigations | 0/3 | 0/5 | 0/3 | 2/4 | 1/25 | 0/1 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Galunisertib + Nivolumab (Cohort 1) Phase 1b | Galunisertib + Nivolumab (Cohort 2) Phase 1b | Galunisertib + Nivolumab (Cohort 3) Phase 1b | Galunisertib + Nivolumab (Cohort 4) Phase 1b | Galunisertib + Nivolumab - Non Small Cell Lung Cancer (NSCLC) Phase 2 | Galunisertib + Nivolumab - Hepatocellular Carcinoma(HCC) Phase 2 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 60.7 ± 15.6 | 47.2 ± 15.8 | 36.0 ± 5.3 | 61.5 ± 9.0 | 61.0 ± 8.4 | 64.0 ± NA | 57.6 ± 12.1 |
| Sex: Female, Male(Participants) | Galunisertib + Nivolumab (Cohort 1) Phase 1b | Galunisertib + Nivolumab (Cohort 2) Phase 1b | Galunisertib + Nivolumab (Cohort 3) Phase 1b | Galunisertib + Nivolumab (Cohort 4) Phase 1b | Galunisertib + Nivolumab - Non Small Cell Lung Cancer (NSCLC) Phase 2 | Galunisertib + Nivolumab - Hepatocellular Carcinoma(HCC) Phase 2 | Total |
|---|---|---|---|---|---|---|---|
| Female | 1 | 1 | 1 | 3 | 9 | 1 | 16 |
| Male | 2 | 4 | 2 | 1 | 16 | 0 | 25 |
| Race (NIH/OMB)(Participants) | Galunisertib + Nivolumab (Cohort 1) Phase 1b | Galunisertib + Nivolumab (Cohort 2) Phase 1b | Galunisertib + Nivolumab (Cohort 3) Phase 1b | Galunisertib + Nivolumab (Cohort 4) Phase 1b | Galunisertib + Nivolumab - Non Small Cell Lung Cancer (NSCLC) Phase 2 | Galunisertib + Nivolumab - Hepatocellular Carcinoma(HCC) Phase 2 | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 | 0 | 0 | 2 |
| White | 2 | 5 | 3 | 3 | 25 | 1 | 39 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Galunisertib + Nivolumab (Cohort 1) Phase 1b | Galunisertib + Nivolumab (Cohort 2) Phase 1b | Galunisertib + Nivolumab (Cohort 3) Phase 1b | Galunisertib + Nivolumab (Cohort 4) Phase 1b | Galunisertib + Nivolumab - Non Small Cell Lung Cancer (NSCLC) Phase 2 | Galunisertib + Nivolumab - Hepatocellular Carcinoma(HCC) Phase 2 | Total |
|---|---|---|---|---|---|---|---|
| United States | 3 | 3 | 2 | 4 | 1 | 0 | 13 |
| Spain | 0 | 2 | 1 | 0 | 24 | 1 | 28 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jan 2015 to primary completion in Dec 2018, 47 months.
Results were first posted in Sep 2021, 2 years 8 months after primary completion. A results delay was requested in Dec 2019.
Of 72 industry-sponsored phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 74. This study's 47 months is close to that.
Counting every sponsor, half of 136 studies reached it within 53 months; a quarter within 38 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LY-2157299